NAMA Policy Statement: “Patient” vs “Client”

The National Alliance for Medication Assisted Recovery (NAMA Recovery) is an organization of methadone patients and patients receiving other medications to treat drug addiction, their families and healthcare and medical professionals. Therefore this website reflects the collaberative efforts between patients and professionals. NAMA Recovery is respected world wide as the premier medication assisted treatment advocacy…

The National Alliance of Methadone Advocates supports the NIH Consensus Statement on Effective Treatment of Heroin Addiction that was facilitated by the National Institute on Drug Abuse and the National Institute of Health. The imprecate of this special statement should be understood in order to realize the impact that it can have on methadone maintenance…

For supporting Methadone Advocacy … and Joining the Struggle! Confirm your Membership and Payment E-Mail Us Here Include your name and address information and the amount.

October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 NIDA Research and SAMHSA Physician Training Combine to Put Care for Opiate Dependence in Hands of Family Doctor. Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA), will now become…

  The first training for certification will include a variety of topics to give advocates a well-grounded understanding of methadone treatment, research, regulations and laws that protect methadone patients and programs.   Addiction and Methadone– Tom Payte, MD (Drug Dependence Associates) and Joycelyn Woods, MA. (NAMA) The biological constructs of addiction will be explained in…

 Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations (i)                 Unsupervised or take-home use.   To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.   (1)   Any patient…